Product

GLP3 20mg

potential to regulate energy balance and lipid metabolism (Jastreboff et al., 2023). Preclinical and clinical studies have demonstrated that GLP-3 (RTA) effectively reduces body weight and improves glycemic control. Research suggests that its mechanism of action involves appetite suppression, increased energy expenditure, and enhanced insulin sensitivity, surpassing the effects of existing monotherapies such as semaglutide (GLP-1 agonist) and tirzepatide (GLP-1/GIP dual agonist) (Tschöp et al., 2023). A phase 2 clinical trial evaluating GLP-3 (RTA) efficacy in obesity management showed an average weight reduction of up to 24% over 48 weeks, significantly outperforming current anti-obesity treatments (Jastreboff et al., 2023). Additionally, patients with T2DM experienced improved glycemic parameters, reduced hemoglobin A1c levels, and enhanced lipid profiles. These findings indicate that GLP-3 (RTA) could be a groundbreaking therapeutic option for metabolic disorders (Kapitza et al., 2023). Further investigations are ongoing to assess GLP-3 (RTA) long-term safety, potential cardiovascular benefits, and its effects on metabolic syndrome components. If proven effective and safe in large-scale trials, GLP-3 (RTA) may represent a new frontier in the treatment of obesity and diabetes, addressing multiple pathways of metabolic dysfunction simultaneously (Tschöp et al., 2023).

Tesamorelin

GHRH Analog.Tesamorelin 10mg IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabled as a drug, food or cosmetic.